[ad_1]
(AWP / SPU) Geneva-based biopharmaceutical company Obseva will start its second listing at SIX this Friday. The first course costs CHF 15.50, which corresponds to a more than 3% compared to the issue price of CHF 15. At the same time, the price of the action is already CHF 16.75 and so up close 12% at most. With a total of more than 45.4 million shares issued, the market capitalization is thus about CHF 680 million, according to a statement released on Friday.
Obseva announced his IPO in early July. The securities are already listed on the Nasdaq American Stock Exchange. With the second listing, the company aims to increase its profile among Swiss and European investors and expand its financing options. In addition, Swiss legislation promises better protection against acquisition.
The registration at SIX is described by CEO and co-founder Ernest Loumaye as a "step" for the company. Swiss institutional and private investors have developed a "global understanding of the health sector". The terminally ill clinical pipeline is developing "on the right track".
Obseva specializes in reproductive medicine and specializes in the development of new therapies for pregnancy-related diseases. Several products are under clinical evaluation, but the company does not yet generate revenue. In the first quarter of 2018, a loss of just under 20 million, the company still had $ 95 million at the time
Source link
